Extended Data Fig. 3: CXCR2 inhibition led to dose-dependent decreases in blood neutrophils.
From: Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance
a, By-patient, serial, peripheral blood NLR for each dose level of AZD5069. Aqua line: responder, Pink line: non-responder. *Outlier with NLR peak of 789% from baseline on cycle 2 day 15 in the setting of salmonella infection. b, Scatterplot of AZD5069 dose administered twice daily versus percentage peripheral blood neutrophil counts on cycle 2 day 1 compared with baseline. c, Scatterplot showing of AZD5069 dose versus mean percentage blood neutrophil count on treatment compared with baseline. For b,c, estimated linear regression lines (pink) with 95% confidence interval (grey band), and correlation coefficients and p-values from the two-sided Spearman’s rank correlation analyses are shown.
